optimized oral treatment
ApprovedSmall molecule
optimized oral treatment is one of 82 small molecule programs targeting Ulcerative Colitis. It is currently in Approved.
2
Indications
5
Total Trials
1
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Skyrizi
AbbViePhase 3
Orencia
Bristol-Myers SquibbPhase 3
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Afimkibart
RochePhase 3
optimized oral treatment
UUniversity Hospital, Lille
Approved
RPC1063
Bristol-Myers SquibbPhase 3
Etrolizumab
RochePhase 3
Propionyl-L-Carnitine
LLee's Pharmaceutical Limited
Phase 3
Simponi
Johnson & JohnsonPreclinical
CT-P13 SC (infliximab)
CCelltrion
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment1 trial
Bipolar Disorder1 trial
Ulcerative Colitis1 trial
Crohn's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for optimized oral treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity Hospital, Lille